

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC20170005452				
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados**)				
Palabras clave utilizadas		oxidoreductase enzyme indoleamine; 2,3- dioxygenase; Cancer; immune-related disorders; VIH.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K 31/4375, A61K 31/4709, A61K 31/496. CPC (Opcional):		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
ORBIT, PATBASE, ESPACENET, USPTO Y EPOQUENET	WO2006135721	21/Diciembre/2006	No aplica	A
	WO2007072017	28/Junio/2007	No aplica	A
	CN102108078	29/Junio/2011	No aplica	A
	WO2007095050	23/Agosto/2007	1 a 19 NIVEL INVENTIVO	Y
	WO2014150677	25/Septiembre/2014	1 a 19 NIVEL INVENTIVO	X,Y
** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.			“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.	

Literatura no patente *Se incluye entre otros, toda la referencia de la literatura no patente.	
Fecha del reporte de búsqueda:	16/11/2018

ESPACENET

Documents cited:	Search	[XY] * WO2006135721 (JANSSEN PHARMACEUTICA NV [BE], et al) [X] 1-3,7,11-15 * page 306, line 10 - page 341, line 10; examples 9-10, 16 * [Y] 4-6,8-10;
		[XY] * WO2007072017 (CHROMA THERAPEUTICS LTD [GB], et al) [X] 1-3,7,11-15 * page 228 - page 235; examples 1-13, 19-25, 42-46, 62-64, 87-90, 183-187; claim - * [Y] 4-6,8-10;
		[XY] * CN102108078 (UNIV SHENYANG PHARMACEUTICAL) [X] 1-3,7,11-15 * table page 32;; example -; claim - * [Y] 4-6,8-10;
		[A] * WO0146199 (LILLY CO ELI [US], et al) [A] 1-15 * example -; claim - *;
		[A] * WO2014150677 (SQUIBB BRISTOL MYERS CO [US]) [A] 1-15 * page 181 - page 182; example -; claim - *
	International search	[Y] * US2004029887 (BHATIA PRAMILA A [US], et al) [Y] 1-2, 42, 48-50 * para [0302], [0345], [0529], [1897]. Example 274; para [2117]-[2119], [2123] *;
		[Y] * US2009275523 (SCHUDOK MANFRED [DE], et al) [Y] 1-2, 42, 48-50 * para [0079]-[0117] *;
		[Y] * WO2014036412 (AMGEN INC [US]) [Y] 50 * pg 3, ln 25-30 *;
		[A] * US5723464 (BRIGHTWELL CHRISTOPHER IAN [GB], et al) [A] 1-2, 42, 48-50 * col 12, ln 28-29 *;
		[A] * US2002016463 (ZABLOCKI JEFF [US], et al) [A] 1-2, 42, 48-50 * Entire Document *
		[Y] - DATABASE PubChem, (20080229), Database accession no. CID 34234433; D1 1-2, 42, 48-50 *; File

USPTO

[Patents](#)
[Trademarks](#)
[Fees and payment](#)
[Help](#)
[MyUSPTO](#)

Public Patent Application Information Retrieval

Patent eBusiness
Patent Application Information Retrieval

Global Dossier
Order Certified Application As Filed
Order Certified File Wrapper
View Order List

14/933,863
IMMUNOREGULATORY AGENTS
082867.000037

Select New Case
Application Data
Transaction History
Image File Wrapper
Patent Term Adjustments
Continuity Data
Fees
Published Documents
Address & Attorney/Agent
Assignments
Display References

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Code	Document Description	Document Category	Page Count	PDF
02-06-2018	COCOUT	Certificate of Correction - Post Issue Communication	PROSECUTION	1	☐
12-19-2017	COCIN	Request for Certificate of Correction	PROSECUTION	3	☐
12-19-2017	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	☐
12-19-2017	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
10-18-2017	COCIN	Request for Certificate of Correction	PROSECUTION	4	☐
10-18-2017	COCIN	Request for Certificate of Correction	PROSECUTION	1	☐
10-18-2017	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	☐
10-18-2017	N417	EFS Acknowledgment Receipt	PROSECUTION	3	☐
10-18-2017	TRAN.LET	Transmittal Letter	PROSECUTION	2	☐

ORBIT

Es seguro | <https://www37.orbit.com/?locale=en&ticket=fc977576-b52e-4273-a1e5-a48ec1c057b3#PatentSearchHistoryPage>

Menu Explorer << Patent family searches (FamPat)

Search Step	Result(s)	Query	Assistant	Source	Action
17	6	16 AND (QUINOLIN)	Search history	FAMPAT	Show results Modify Save Alert Delete
16	35	14 AND (IMMUNE)	Search history	FAMPAT	Show results Modify Save Alert Delete
15	0	14 AND VIH	Search history	FAMPAT	Show results Modify Save Alert Delete
14	75	13 AND (CANCER)	Search history	FAMPAT	Show results Modify Save Alert Delete
13	175	11 AND 12	Search history	FAMPAT	Show results Modify Save Alert Delete
12	248	(OXIDOREDUCTASE AND ENZYME AND INDOLEAMINE)/TX/BI/SA/KEYWIN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
11	21888770	("2" OR 3-DIOXYGENASE)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete

Easy search Save strategy

Menu Filter Explorer << 6 results for 16 AND (QUINOLIN) - Collection: FAMPAT

Filter options

Legal status

Alive (6)

Dead (0)

1st application year

After 2015 (0)

2011-2015 (6)

2006-2010 (0)

2001-2005 (0)

Before 2001 (0)

Assignee

Litigations

Oppositions

#	Title	Publication number	1st app. date	Applicant/Assignee	Relevance	Litigation
1	8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tyrosine kinase inhibitors and gcn2 serin kinase inhibitors	CA2863723	2013-01-22	MERCK; MER...	100 %	
2	Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer	CA2903903	2014-02-10	MERCK; MER...	72 %	
3	9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents	CA2903901	2014-02-11	MERCK; MER...	70 %	
4	Triazolo[4,5-d]pyrimidine derivatives	CA2862694	2012-12-21	MERCK; MER...	65 %	
5	Triazolo[4,5-d]pyrimidine derivatives	CA2866450	2013-02-14	MERCK; MER...	64 %	
6	Immunoregulatory agents	CA2964290	2015-11-04	FLEXUS BIOSC...	62 %	

Preview Image

8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tyrosine kinase inhibitors and gcn2 serin kinase inhibitors

PATBASE

PatBase

Username: SIC6@patbase.com
Subaccount: NELSON RICARDO VELASCO

Menu Search History Session Folder Order Help Logoff

Search 2: STAC=(oxidoreductase enzyme indoleamine; 2,3- dioxxygenase)
Results 4

Explore search Edit and resend search

Speed up your search by NOT using the 'S' command for simple searches.
Searches using the 'S' commands run slower than most normal searches. When searching for only keywords and not using operators like AND or NOT or left hand truncation then there is no need to use an 'S' command.
E.g search TAC=(golf or ball) instead of STAC=(golf or ball).

#	Search query	Results	Options
2	STAC=(oxidoreductase enzyme indoleamine; 2, 3- dioxxygenase)	4	View Browse Hits Optimise more...
1	IC=(A61K 31/16 or C07C 13/02 or C07C 13/16)	3	View Browse Hits Optimise more...

Information Shortcuts

Command Reference

Bibliographic data

Textual data

PatBase

Username: SIC6@patbase.com
Subaccount: NELSON RICARDO VELASCO

Menu Search History Session Folder Order Help Logoff

Search 2: "STAC=(oxidoreductase enzyme indoleamine; 2, 3- dioxxygenase) " 1.4 of 4

Display results

Display format: Classic Sorted by: Publication date asc Print Save/export Snapshot Visual explorer Analytics

1) Family number: 61062982 (US2017112785A) Similar Translate Full-text Status Citations

Title: [EN] IMMUNOREGULATORY AGENTS

Abstract: Source: US2017112785A [EN] Compounds that modulate the **oxidoreductase enzyme** indoleamine **2,3-dioxxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxxygenase is also provided.

Figure 1

EPOQUENET



New connection on: : 19-11-2018 : 15:27:44 - Last disconnection on: : 15-11-2018 : 16:18:28

V 4.0.0.44803(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200#(D201820)) (RPM D201820)

Welcome to EPOQUE Rebuild under the Production Environment

[No database/cluster active] ..FI EPOQUENET

Unknown database/cluster. Use the command ..FI (CL) in order to check the name of the
databases/clusters available. *ERROR(-50416)*

[No database/cluster active] ..FI

Select a database: ..FI EPODOC



Database: EPODOC

Records: 111.284.838

Terms: 1.472.862.818

Occurrences: 22.515.320.132

Last Update: 20181118

[EPODOC: SS 1] Fungicidal and Carboxamide and derivatives

Results in EPODOC 161

[SS 2] difluoromethyl and nicotinic and indanyl and carboxamide

Results in EPODOC 25

[SS 3] 1 and 2

Results in EPODOC 0

[SS 4] oxidoreductase AND enzyme AND indoleamine

Results in EPODOC **29**

[SS 5] Cancer

Results in EPODOC **220.227**

[SS 6] immune AND related AND disorders

Results in EPODOC **2.208**

[SS 7] 4 AND 5 AND 6

Results in EPODOC **29**

[SS 8] VIH

Results in EPODOC **174**

[SS 9] 8 AND 7

Results in EPODOC **0**

[SS 10] QUINOLIN

Results in EPODOC **2.915**

[SS 11] 10 AND 8

Results in EPODOC **0**

[SS 12] 7




1/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - **US2018325889** A1 20181115



2/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.




3/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [CN107427499](#) A 20171201



4/29 © EPODOC / EPO

TI - IMMUNIREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.




PN - [PH12017500629](#) A1 20170925

5/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.

PN - [PH12017500604](#) A1 20170904




6/29 © EPODOC / EPO

TI - Immunoregulatory agents

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune -related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [CN107205970](#) A 20170926



TI - IMMUNOREGULATORY AGENTS.

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [MX2017005646](#) A 20170714



TI - IMMUNOREGULATORY AGENTS.

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune -related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.

PN - [MX2017005462](#) A 20170728




9/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS.

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.

PN - [MX2017005729](#) A 20170728




10/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS.

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [MX2016015610](#) A 20170713



11/29 © EPODOC / EPO

TI - Immunoregulatory agents

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine**



2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [CN106999450](#) A 20170801

12/29 © EPODOC / EPO

TI - (A1)
IMMUNOREGULATORY AGENTS
- (B2)
Immunoregulatory agents

AB - (A1 B2)
Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [US2017197973](#) A1 20170713



13/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described



herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [US2017143649](#) A1 20170525

14/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [CA2964290](#) A1 20160512



15/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or



prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [CA2964297](#) A1 20160512

16/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [CA2964276](#) A1 20160512



17/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated



by **indoleamine** 2,3-dioxygenase is also provided.


PN - [US2017112785](#) A1 20170427

18/29 © EPODOC / EPO

TI - Immunoregulatory agents

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine** 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine** 2,3-dioxygenase is also provided.


PN - [AU2015342940](#) A1 20170427



19/29 © EPODOC / EPO

TI - Immunoregulatory agents

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine** 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine** 2,3-dioxygenase is also provided.




PN - [AU2015342944](#) A1 20170420

20/29 © EPODOC / EPO

TI - Immunoregulatory agents

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.




PN - [CN106535884](#) A 20170322

21/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.




PN - [CA2951259](#) A1 20151210

22/29 © EPODOC / EPO

TI - Immunoregulatory agents

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions



containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [TW201630886](#) A 20160901

23/29 © EPODOC / EPO

TI - Immunoregulatory agents

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [TW201630866](#) A 20160901



24/29 © EPODOC / EPO

TI - (A1)
IMMUNOREGULATORY AGENTS
- (B2)
Immunoregulatory agents

AB - (A1 B2)
Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described



herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [US2016137653](#) A1 20160519

25/29 © EPODOC / EPO

TI - (A1)
IMMUNOREGULATORY AGENTS
- (B2)
Immunoregulatory agents

AB - (A1 B2)
Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [US2016137652](#) A1 20160519



26/29 © EPODOC / EPO

TI - (A2 A3)
IMMUNOREGULATORY AGENTS

AB - (A2 A3)
Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3-dioxygenase**, and compositions containing the compounds, are described



herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune-related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.

PN - [WO2016073774](#) A2 20160512

27/29 © EPODOC / EPO


TI - (A2 A3)

IMMUNOREGULATORY AGENTS

AB - (A2 A3)

Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer**- and **immune -related disorders**, that are mediated by **indoleamine 2,3-dioxygenase** is also provided.


PN - [WO2016073738](#) A2 20160512



28/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine 2,3- dioxygenase**, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions,



including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine** 2,3-dioxygenase is also provided.

PN - [WO2016073770](#) A1 20160512

29/29 © EPODOC / EPO

TI - IMMUNOREGULATORY AGENTS

AB - Compounds that modulate the **oxidoreductase enzyme indoleamine** 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, **disorders** and conditions, including **cancer-** and **immune-related disorders**, that are mediated by **indoleamine** 2,3-dioxygenase is also provided.

PN - [WO2015188085](#) A1 20151210

